Technical Analysis for RARX - Ra Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 46.75 0.32% 0.15
RARX closed up 0.32 percent on Friday, November 15, 2019, on 34 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Flat
See historical RARX trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 2.43%
Crossed Above 20 DMA Bullish 2.43%
Crossed Above 50 DMA Bullish 2.43%
MACD Bullish Centerline Cross Bullish 2.43%
MACD Bullish Signal Line Cross Bullish 2.43%
New 52 Week Closing High Bullish 2.43%
New Uptrend Bullish 2.43%
Pocket Pivot Bullish Swing Setup 2.43%
Volume Surge Other 2.43%
Narrow Range Bar Range Contraction 2.43%

Older signals for RARX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Its peptide chemistry platform delivers enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. The company's lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It also develops Factor D inhibition for age-related macular degeneration and geographic atrophy; Oral C5 inhibitor for refractory generalized myasthenia gravis, lupus nephritis, and central nervous system (CNS) diseases; C1s inhibition for autoimmune/CNS diseases. The company has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Medicine Biopharmaceutical Medical Specialties Diseases Immunology Antibodies Autoimmune Diseases Rare Diseases Autoimmunity Age Related Macular Degeneration Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Myasthenia Gravis Lupus Nephritis Pnh Therapeutics For The Treatment Of Diseases
Is RARX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 47.35
52 Week Low 13.73
Average Volume 1,247,210
200-Day Moving Average 28.1086
50-Day Moving Average 36.4643
20-Day Moving Average 46.704
10-Day Moving Average 46.802
Average True Range 0.6919
ADX 60.62
+DI 44.9094
-DI 11.9416
Chandelier Exit (Long, 3 ATRs ) 45.2743
Chandelier Exit (Short, 3 ATRs ) 48.1196
Upper Bollinger Band 47.2406
Lower Bollinger Band 46.1674
Percent B (%b) 0.54
BandWidth 2.297876
MACD Line 2.5173
MACD Signal Line 3.271
MACD Histogram -0.7537
Fundamentals Value
Market Cap 1.06 Billion
Num Shares 22.6 Million
EPS -2.84
Price-to-Earnings (P/E) Ratio -16.46
Price-to-Sales 0.00
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 47.10
Resistance 3 (R3) 47.09 46.97 47.04
Resistance 2 (R2) 46.97 46.88 46.97 47.02
Resistance 1 (R1) 46.86 46.83 46.92 46.87 47.00
Pivot Point 46.74 46.74 46.77 46.74 46.74
Support 1 (S1) 46.63 46.65 46.69 46.64 46.50
Support 2 (S2) 46.51 46.60 46.51 46.48
Support 3 (S3) 46.40 46.51 46.46
Support 4 (S4) 46.41